Emergingby GlyphUnity Biotechnology stockholders approve dissolution
A special meeting approved the plan to dissolve the senolytics company.
Longevity biotechsec.gov
Unity Biotechnology
Public companyUS1 field
Where it works
| Technology | ||
|---|---|---|
| Longevity biotechDeveloped senolytic drugs such as UBX1325 for eye disease; stockholders approved its dissolution in 2025. | Developed senolytic drugs such as UBX1325 for eye disease; stockholders approved its dissolution in 2025. | unitybiotechnology.com |
Events
Unity Biotechnology cuts all staff after ASPIRE data
Unity approved a reduction in force affecting all employees and began exploring strategic alternatives.
Longevity biotechsec.gov
Senolytic UBX1325 results for diabetic macular edema published
NEJM Evidence published safety and efficacy data for Unity's senolytic UBX1325 in diabetic macular edema.
Longevity biotechdoi.org
About
- Source
- unitybiotechnology.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Oct 20, 2026
- Across Glyph
- Unity Biotechnology on Companies
Unity Biotechnology
Joined in Longevity biotech. Developed senolytic drugs such as UBX1325 for eye disease; stockholders approved its dissolution in 2025.
Unity Biotechnology
Added in Longevity biotech. Developed senolytic drugs such as UBX1325 for eye disease; stockholders approved its dissolution in 2025.